
BLCO Stock Forecast & Price Target
BLCO Analyst Ratings
Bulls say
Bausch & Lomb has raised its revenue guidance for 2025 to a range of $5,050-$5,150 million, indicating a projected growth rate of 5-7% on a constant currency basis, alongside an expected adjusted EBITDA increase to $860-$910 million. The company is experiencing strong growth in its premium intraocular lens offerings, with notable contributions from the enVista and LUX platforms, and its product MIEBO has reported an impressive 110-111% year-over-year prescription growth. Additionally, the firm has benefited from foreign exchange tailwinds contributing $25 million to its full-year revenue, supporting a robust financial outlook despite potential tariff impacts.
Bears say
Bausch & Lomb is experiencing challenges in maintaining its competitive edge in the ophthalmology market due to increased pricing pressure on products like XIIDRA, as well as limited pipeline development and investments made during its prior association with Bausch Health. The company faces significant risks, including macroeconomic factors that may impact elective procedures like cataract surgeries, fluctuations in emerging markets, and high leverage from the acquisition of Xiidra, all of which could adversely affect growth and investor confidence. Projected financial metrics indicate a projected adjusted EPS of $0.75 and high net debt of $13.25 per share, reflecting concerns around long-term profitability and growth sustainability.
This aggregate rating is based on analysts' research of Bausch + Lomb Corp and is not a guaranteed prediction by Public.com or investment advice.
BLCO Analyst Forecast & Price Prediction
Start investing in BLCO
Order type
Buy in
Order amount
Est. shares
0 shares